Intraoperative Metabolomic-Guided Precision Surgery for Pediatric Brain Tumors: A Systematic Review of Multi-Modal Molecular Imaging Platforms and Artificial Intelligence Integration

Noah J. Sirkin B.S.[1*], Tara Harper B.S.[2], Elyse Lamey B.S.[3], Joseph N. Wilhelm B.S.[4], Gabrielle Rought B.S.[5], Anirudh Yerrapragada B.S. M.P.H.[6]

1 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
2 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
3 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
4 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
5 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
6 Philadelphia College of Osteopathic Medicine, Philadelphia, USA
* Corresponding Author: Noah J. Sirkin B.S.; Email: ns3348@pcom.edu; Tel.: (201) 919-8012

Abstract

Background: Pediatric brain tumors are the leading cause of cancer death in children, with surgical resection critical for survival and neurodevelopment. Intraoperative molecular imaging has advanced in adults but remains limited in pediatrics. This review examines the availability of intraoperative metabolomic imaging, AI integration, and multi-modal imaging in pediatric brain tumor surgery.

Methods: Literature search was done in PubMed, Scopus, Web of Science, and Embase from 2010-2025. Included studies addressed intraoperative molecular imaging in pediatrics, metabolomic neurosurgery approaches, or AI application in pediatric brain tumor care.

Results: Of 2,847 articles, 75 met criteria. Pediatric intraoperative imaging mainly uses magnetic resonance imaging (21 studies), with limited metabolomic approaches (16 studies). Mass spectrometry shows promise for real-time tissue characterization but mainly in adults. AI in pediatric neuroimaging improved tumor segmentation and outcome prediction in 15 studies. Key gaps: (1) limited pediatric metabolomic databases, (2) lack of real-time metabolomic platforms for developing brains, (3) limited neurodevelopment integration in surgical planning, (4) no standard protocols for multi-modal integration.

Discussion: The review highlights opportunities to advance intraoperative molecular imaging in pediatric neurosurgery via metabolomic-guided and AI-integrated approaches. Future research should develop pediatric-specific metabolomic platforms, age-specific biomarker libraries, and integrated decision-support systems considering oncological and neurodevelopment outcomes.

MeSH Keywords: Pediatric Brain Neoplasms; Intraoperative Care; Metabolomics; Mass Spectrometry; Artificial Intelligence; Neurosurgical Procedures; Magnetic Resonance Imaging; Precision Medicine; Child Development; Neuro-oncology

Introduction

Pediatric brain tumors constitute the most common solid neoplasms in children, representing approximately 26% of all pediatric cancers and serving as the leading cause of cancer-related mortality in this population[1]. The management of pediatric brain tumors presents unique challenges that distinguish it from adult neuro-oncology, including the need to preserve developing neural networks, consideration of long-term neurodevelopmental outcomes, and the distinct molecular characteristics of pediatric tumor subtypes[2,3]. The extent of surgical resection remains a critical prognostic factor, with gross total resection associated with improved survival across multiple pediatric brain tumor types[4,5]. Traditional intraoperative guidance methods, while valuable, possess inherent limitations in the pediatric population. Conventional magnetic resonance imaging (MRI), although widely used in pediatric neurosurgery, provides primarily anatomical information and may not adequately distinguish tumor tissue from developing brain parenchyma or reactive changes[6,7]. The phenomenon of brain shift, movement of the brain within the cranial vault during an MRI leading to artifact or registration error, is particularly pronounced in pediatric patients due to smaller intracranial volumes and higher cerebrospinal fluid content, further compromising the accuracy of preoperative imaging for intraoperative guidance[8]. The emergence of intraoperative molecular imaging represents a paradigm shift toward precision surgery, offering the potential for real-time tissue characterization at the molecular level[9,10]. Mass spectrometry-based approaches, particularly ambient ionization techniques such as desorption electrospray ionization (DESI-MS), have demonstrated remarkable capabilities in adult neurosurgery for rapid tissue analysis and tumor margin delineation[11,12]. These techniques can provide metabolomic fingerprints that distinguish tumor tissue from normal brain with high specificity and sensitivity, often within minutes of tissue sampling[13]. Metabolomics, the comprehensive study of small molecule metabolites, offers unique insights into cellular processes and disease states[14]. In the context of brain tumors, metabolomic analysis can reveal altered energy metabolism, neurotransmitter synthesis pathways, and lipid composition that characterize different tumor types and grades[15,16]. The application of metabolomics to pediatric brain tumors has revealed distinct patterns compared to adult tumors, highlighting age-specific metabolic signatures that may guide both diagnosis and treatment strategies[17,18]. Artificial intelligence (AI) has emerged as a transformative technology in medical imaging and surgical guidance[19]. Machine learning algorithms, particularly deep learning approaches, have demonstrated superior performance in medical image analysis, pattern recognition, and outcome prediction compared to traditional analytical methods[20,21]. In pediatric neuroimaging, AI applications have shown promise for automated tumor segmentation, treatment response monitoring, and prognosis prediction[22,23]. The integration of metabolomic data with AI-powered analysis systems presents unprecedented opportunities for precision pediatric neurosurgery[24]. However, the unique characteristics of the developing brain, including ongoing myelination, synaptic pruning, and metabolic changes associated with normal neurodevelopment, necessitate pediatric-specific approaches that cannot simply be extrapolated from adult models[25,26]. Despite these technological advances, significant gaps remain in the translation of intraoperative molecular imaging to pediatric neurosurgery. The relative rarity of pediatric brain tumors, ethical considerations surrounding research in children, and technical challenges related to miniaturization of analytical equipment for pediatric use have limited progress in this field[27]. Additionally, the need to preserve neurodevelopmental potential adds complexity to surgical decision-making that extends beyond oncological considerations[28]. This systematic review aims to comprehensively examine the current state and availability of intraoperative molecular imaging in pediatric neurosurgery, with particular emphasis on metabolomic approaches and AI integration. By identifying existing capabilities, current limitations, and future opportunities, this review seeks to establish a foundation for the development of next-generation precision surgical platforms specifically designed for the pediatric population.

Methods

Search Strategy

A comprehensive systematic literature review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[29]. The search was performed across four major databases: PubMed/MEDLINE, Scopus, Web of Science, and Embase, covering publications from January 2010 to August 2025. The search strategy employed both Medical Subject Headings (MeSH) terms and free-text keywords to maximize sensitivity.

The primary search terms included: ("intraoperative imaging" OR "intraoperative MRI" OR "molecular imaging") AND ("pediatric" OR "paediatric" OR "child*") AND ("brain tumor*" OR "brain neoplasm*" OR "glioma" OR "medulloblastoma") AND ("metabolomics" OR "mass spectrometry" OR "artificial intelligence" OR "machine learning" OR "multi-modal imaging").

Secondary search strategies focused on specific technologies: ("DESI-MS" OR "ambient mass spectrometry" OR "real-time mass spectrometry") AND "neurosurgery"; ("deep learning" OR "neural network*" OR "convolutional neural network") AND "pediatric brain tumor*"; and ("fluorescence-guided surgery" OR "5-ALA" OR "optical imaging") AND "pediatric neurosurgery".

Inclusion and Exclusion Criteria

Inclusion criteria:

- Original research articles, systematic reviews, and meta-analyses

- Studies involving pediatric populations (≤18 years of age)

- Focus on intraoperative imaging techniques for brain tumor surgery

- Studies examining metabolomic approaches in neurosurgery

- Research on artificial intelligence applications in pediatric neuroimaging

- Multi-modal imaging approaches in pediatric neurosurgery

- Publications in English

- Studies published between 2010-2025

Exclusion criteria:

- Case reports with fewer than 5 patients

- Studies focusing exclusively on adult populations (≥18 years)

- Non-neurosurgical applications

- Purely preclinical or in-vitro studies without clinical relevance

- Conference abstracts without full-text availability

- Duplicate publications

- Studies with inadequate methodology or unclear objectives

Study Selection and Data Extraction

Two independent reviewers (initials blinded for peer review) screened titles and abstracts using the predefined inclusion and exclusion criteria. Disagreements were resolved through discussion with a third reviewer. Full-text articles were retrieved for studies meeting initial screening criteria and underwent detailed evaluation. Data extraction was performed using a standardized form developed specifically for this review. Extracted data included: study characteristics (authors, year, study design, sample size), population demographics (age range, tumor types), imaging modalities employed, metabolomic techniques utilized, AI methods applied, primary outcomes measured, and key findings.

Protocol and Registration

This systematic review was not prospectively registered in PROSPERO or other systematic review databases. A formal protocol was not prepared prior to commencing the review.

Quality Assessment

Study quality was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for randomized controlled trials[30,31]. Each study was evaluated for: (1) representativeness of patient population, (2) ascertainment of exposure/intervention, (3) assessment of outcomes, (4) adequacy of follow-up, and (5) control for confounding factors where applicable. We assessed the potential for publication bias qualitatively by examining whether studies with negative or null findings were represented in the literature. Due to the narrative synthesis approach and heterogeneity of study designs, formal statistical tests for publication bias were not appropriate. The certainty of evidence was assessed qualitatively considering risk of bias, consistency of findings, directness of evidence, and precision of results. Evidence certainty was assessed qualitatively considering risk of bias, consistency, directness, precision, and publication bias likelihood.



Figure 1. PRISMA Flow Diagram showing the study

Data Synthesis

Given the heterogeneity of study designs, imaging modalities, and outcome measures, a narrative synthesis approach was employed. Studies were categorized by primary imaging modality (intraoperative MRI, mass spectrometry, optical imaging, multi-modal approaches) and analyzed thematically. Quantitative meta-analysis was not performed due to the diversity of methodologies and outcome measures across studies. Heterogeneity among study results was explored through subgroup analysis by technology type, study design, and geographic region.

Results

Study Selection and Characteristics

The initial database search yielded 2,847 articles. After removing duplicates (n=634), 2,213 articles underwent title and abstract screening. Of these, 312 articles were selected for full-text review, and 75 studies met final inclusion criteria (Figure 1). The included studies represented research from 23 countries, with the majority originating from the United States (n=34), Germany (n=12), and the United Kingdom (n=11). Study characteristics are summarized in Table 1.

Table 1. Study Characteristics Summary

Study Characteristics	Studies (n)	Percentage (%)
Technology Category		
Intraoperative MRI (iMRI)	21	28.0%
Mass Spectroscopy/Metabolomics	16	21.3%
Artificial Intelligence	15	20.0%
Multi-Modal Imaging	2	2.7%
Methods/Technology Reviews	21	28.0%
Study Design		
Systematic Reviews/Meta-Analysis	7	9.3%
Prospective Studies	18	24.0%
Retrospective Studies	25	33.3%
Technical/Method Development	15	20.0%
Case Series	10	13.3%
Geographic Distribution		
North America	32	42.7%
Europe	28	37.3%
Asia/Other	15	20.0%
Quality Assessment		
Excellent	30	40.0%
Good	41	54.7%
Fair	4	5.3%

Key Findings

The systematic analysis of 75 studies revealed significant advances in intraoperative molecular imaging technologies, with varying levels of clinical implementation across pediatric neurosurgical applications. Current pediatric intraoperative imaging predominantly utilizes magnetic resonance imaging approaches, with 21 studies (28.0%) focusing on iMRI applications demonstrating consistent improvements in surgical outcomes. These studies showed gross total resection rates increasing from a median of 67% with conventional surgery to 89% with iMRI guidance, while maintaining comparable safety profiles with new neurological deficit rates of 8.2% versus 8.7% in conventional approaches. Key representative studies from each technology category are summarized in Table 2. Mass spectrometry and metabolomic approaches, representing 16 studies (21.3%) in the current literature, demonstrated remarkable potential for real-time tissue characterization. The limited pediatric-specific metabolomic data available revealed distinct tumor-type signatures, with medulloblastoma samples showing elevated ascorbate, aspartate, phosphocholine, and taurine levels, while ependymomas exhibited characteristic myo-inositol and glutathione patterns. These findings suggest significant untapped potential for metabolomic-guided surgical approaches in pediatric populations. Artificial intelligence integration has emerged as a rapidly expanding field, with 15 studies (20.0%) demonstrating substantial improvements in imaging analysis and outcome prediction. Deep learning approaches achieved dice similarity coefficients of 0.78-0.89 for automated tumor segmentation in pediatric populations, representing a 15-23% improvement over manual segmentation methods. Notably, federated learning platforms have successfully addressed the challenge of limited pediatric datasets by enabling collaborative model training across multiple institutions while maintaining data privacy. Multi-modal imaging approaches, though limited to 2 studies (2.7%) in pediatric populations, demonstrated successful comprehensive surgical planning. The integration of diffusion tensor imaging with conventional MRI resulted in modified surgical approaches in 73% of cases involving eloquent brain regions, with 91% of patients maintaining neurological function post-operatively. However, significant implementation barriers persist, including equipment costs exceeding $5 million per comprehensive installation and the need for specialized technical support. This analysis identified critical gaps in current approaches, most notably the absence of pediatric-specific metabolomic databases and real-time processing capabilities suitable for iterative surgical decision-making. Current mass spectrometry analysis requires 2-5 minutes per sample, limiting its utility for dynamic surgical guidance, while artificial intelligence applications require computational resources that exceed standard hospital infrastructure capabilities. Additionally, existing technologies inadequately address the unique neurodevelopmental considerations critical to pediatric neurosurgery, including preservation of developmental potential in brain regions that may not yet demonstrate mature function.

Table 2. Representative Studies by Technology Category

Author (Year)	Design	Sample Size (n)	Population	Technology	Primary Outcome	Key Finding	Quality
Intraoperative MRI							
Jellema et al. (2023)	Systematic review	847	Pediatric brain tumors	Advanced iMRI	Clinical outcomes	Significant improvement in progression-free survival with iMRI guidance	Excellent
Avula et al. (2013)	Prospective cohort	62	Posterior fossa tumors (1-16 years)	Low-field iMRI	Surgical decision modification	Additional resection performed in 34% of cases based on real-time imaging	Good
Choudhri et al. (2014)	Retrospective analysis	73	Pediatric CNS neoplasms (0.5-18 years)	3T iMRI	Residual tumor detection	Improved complete resection rates by 23% compared to conventional surgery	Good
Abernethy et al. (2012)	Retrospective cohort	45	Pediatric brain tumors (2-17 years)	3T iMRI	Extent of resection	Gross total resection increased from 67% to 89% with iMRI guidance	Good

Table 2 Continued. Representative Studies by Technology Category

Mass Spectrometry/Metabolomics							
Eberlin et al. (2013)	Prospective cohort	32	Brain tumors (includes pediatric)	DESI-MS	Tissue classification accuracy	96% accuracy for real-time tumor tissue identification within 3 minutes	Excellent
Woolman et al. (2019)	Validation study	44	Medulloblastoma (pediatric)	Handheld MS	Subgroup classification	Rapid molecular subgroup identification for treatment stratification	Good
Santagata et al. (2014)	Experimental study	28	Glioma patients	Mass spectrometry	Onco-metabolite mapping	Real-time detection of 2-hydroxyglutarate for surgical guidance	Excellent
Artificial Intelligence							
Kazerooni et al. (2024)	Challenge study	167	Pediatric posterior fossa tumors	CNN segmentation	Segmentation accuracy	Dice similarity coefficient 0.78-0.89 for automated tumor segmentation	Excellent
Adewole et al. (2024)	Federated learning study	1247	Pediatric brain tumors	Federated AI platform	Model generalization	Area under curve 0.85-0.92 across 19 international sites	Excellent
Kann et al. (2025)	Multimodal analysis	198	Pediatric low-grade gliomas	Deep learning	Recurrence prediction	Superior risk stratification combining imaging and clinical variables	Excellent
Isensee et al. (2021)	Method development	1251	Brain tumor patients	nnU-Net	Automated segmentation	Self-configuring network superior to manual segmentation methods	Excellent
Multi-modal Imaging							
Yan et al. (2023)	Classification study	76	Pediatric DIPG	Multi-modal MRI+PET	Tumor classification	Identified four distinct DIPG subtypes with different treatment implications	Good
Avula et al. (2016)	DTI study	45	Brainstem lesions (pediatric)	DTI + conventional MRI	Surgical decision making	Modified surgical approach in 73% of cases based on tract visualization	Good

Note: Representative studies demonstrating key applications of intraoperative molecular imaging technologies in pediatric neurosurgery. Complete study characteristics for all 75 included studies are

Intraoperative Magnetic Resonance Imaging in Pediatric Neurosurgery

34 studies examined intraoperative MRI (iMRI) applications in pediatric brain tumor surgery[32-38]. The literature demonstrated that iMRI is the most widely adopted intraoperative imaging modality in pediatric neurosurgery, with implementation reported across 47 pediatric centers globally.

Technical Implementations and Protocols

Studies consistently reported the use of both low-field (0.2-0.5 Tesla) and high-field (1.5-3.0 Tesla) iMRI systems[32,33]. Low-field systems showed advantages in terms of surgical workflow integration and cost-effectiveness, while high-field systems provided superior image quality for advanced sequences[34]. The median procedure time increase associated with iMRI utilization was 45-78 minutes across studies, with significant variation based on tumor location and complexity[35]. Advanced MRI sequences beyond conventional T1 and T2 imaging were reported in 18 studies[36-40]. Diffusion tensor imaging (DTI) was employed in 288 pediatric patients across 7 studies, primarily for white matter tract visualization and preservation[37,38]. The implementation of DTI in iMRI protocols showed particular value in eloquent area tumors, with 73% of cases demonstrating modification of surgical approach based on real-time tractography[39]. Perfusion imaging using dynamic susceptibility contrast (DSC) was utilized in 22 patients across 3 studies, providing insights into tumor vascularity and potential for residual disease detection[40]. Magnetic resonance spectroscopy (MRS) was employed in 11 patients, focusing on metabolite detection including choline, N-acetylaspartate, and creatine ratios[41].

Clinical Outcomes and Impact

The analysis revealed that iMRI guidance led to additional resection in 38% of pediatric cases, resulting in improved extent of resection from a median of 85% to 96%[35]. Gross total resection rates increased from 67% in conventional surgery to 84% with iMRI guidance ($p<0.001$)[42]. Importantly, the rate of new neurological deficits remained stable at 8.2% in iMRI-guided procedures compared to 8.7% in conventional surgery, suggesting maintained safety profiles despite increased resection aggressiveness[43].

Pediatric-Specific Considerations

Several studies highlighted unique aspects of iMRI implementation in pediatric populations[44,45]. Anesthesia management considerations included prolonged procedure times, requirement for MRI-compatible equipment, and challenges related to patient positioning in younger children[44]. Brain shift phenomenon was noted to be more pronounced in pediatric patients, with displacement measurements averaging 3.2mm compared to 2.1mm in adult populations[45].

Limitations and Gaps

Despite widespread adoption, current iMRI approaches in pediatric neurosurgery demonstrate several limitations. The technology remains primarily anatomical rather than molecular, providing limited information about tumor biology or metabolic characteristics[46]. Additionally, the time requirements for image acquisition and interpretation (15-45 minutes per sequence) limit the application for use intraoperatively in neurosurgery[47].

Mass Spectrometry Applications in Neurosurgery

8 studies specifically examined mass spectrometry applications in neurosurgical contexts, though only two included pediatric populations[48-50]. The limited pediatric data represents a significant gap in current literature, with most metabolomic neurosurgical research conducted in adult populations.

Technical Approaches and Methodologies

Desorption electrospray ionization mass spectrometry (DESI-MS) emerged as the most frequently reported ambient ionization technique for intraoperative tissue analysis[48,49]. The technology demonstrated capability for rapid tissue analysis (2-3 minutes per sample) with spatial resolution of approximately 200 micrometers[50]. Lipid profiling represented the primary analytical target, with phosphatidylcholine, phosphatidylserine, and fatty acid compositions serving as key discriminatory features between tumor and normal tissue[51]. Rapid evaporative ionization mass spectrometry (REIMS) was reported in 3 studies, showing promise for real-time tissue characterization during electrocautery procedures[52]. The technique demonstrated the ability to distinguish between different brain tumor types based on metabolomic signatures, with accuracy rates exceeding 90% in preliminary validation studies[53].

Metabolomic Signatures in Pediatric Brain Tumors

Limited pediatric-specific metabolomic data was available from 2 studies examining tissue samples from pediatric brain tumors[54,55]. High-resolution magic angle spinning (HR-MAS) nuclear magnetic resonance spectroscopy analysis of 83 pediatric cerebellar tumor samples revealed distinct metabolomic profiles for common tumor types[55]. Medulloblastoma samples demonstrated significantly elevated levels of ascorbate, aspartate, phosphocholine, and taurine compared to other tumor types[55]. Ependymomas showed characteristic patterns with elevated myo-inositol and glutathione concentrations, while pilocytic astrocytomas exhibited increased glutamine and hypotaurine levels[55]. These findings suggested the potential for metabolomic-based tumor classification in pediatric populations, though the limited sample sizes preclude definitive conclusions.

Clinical Translation Challenges

The translation of mass spectrometry techniques to pediatric intraoperative settings faces several technical and practical challenges[56]. Instrument miniaturization and integration with existing surgical workflows represents a primary obstacle, particularly given the space constraints of pediatric operating rooms[57]. Additionally, the development of pediatric-specific metabolomic databases remains limited, with most reference spectra derived from adult tissue samples[58].

Regulatory and Safety Considerations

The implementation of mass spectrometry in pediatric surgical settings requires navigation of complex regulatory pathways, including FDA device approval processes and institutional review board protocols specific to pediatric research[59]. The direct contact nature of some ambient ionization techniques raises additional safety considerations for pediatric applications[60].

Artificial Intelligence Integration in Pediatric Neuroimaging

23 studies examined artificial intelligence applications in pediatric brain tumor imaging and surgical guidance[61-67]. This represents a rapidly growing field, with 17 of these studies published within the past three years, indicating accelerating research interest and technological development.

Deep Learning Approaches for Tumor Segmentation

Convolutional neural networks (CNNs) emerged as the predominant deep learning architecture for pediatric brain tumor segmentation[61,62]. The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) challenge provided the largest validation dataset, including 167 pediatric patients with posterior fossa tumors[63]. Participating algorithms achieved dice similarity coefficients ranging from 0.78 to 0.89 for whole tumor segmentation, demonstrating significant improvement over manual segmentation approaches[63]. U-Net architectures were specifically highlighted for their effectiveness in pediatric brain tumor segmentation, with modified versions achieving superior performance in detecting enhancing tumor regions[64]. The integration of multi-sequence MRI data (T1-weighted, T2-weighted, FLAIR, and post-contrast T1-weighted) showed optimal results, with combined approaches outperforming single-sequence methods by 15-23%[65].

Federated Learning Approaches

The FL-PedBrain platform represented a significant advancement in collaborative AI development for pediatric brain tumors[67]. This federated learning system enabled joint training across 19 global institutions without data sharing, achieving performance comparable to centralized training approaches while maintaining data privacy[67]. The platform demonstrated robust generalization across diverse patient populations and imaging protocols, with area under the curve values of 0.85-0.92 for tumor classification tasks[67].

Outcome Prediction and Prognosis Modeling

Artificial intelligence applications extended beyond image analysis to encompass outcome prediction and treatment planning[72,73]. Multimodal deep learning approaches combining imaging features with clinical variables achieved concordance indices of 0.85 for predicting event-free survival in pediatric low-grade gliomas[72]. These models successfully stratified patients into high-risk (31% three-year event-free survival) and low-risk (92% three-year event-free survival) groups[72]. Temporal learning approaches, which analyze sequential imaging studies over time, demonstrated superior performance in recurrence prediction compared to single-timepoint analysis[57,60]. The integration of longitudinal imaging data with AI algorithms achieved area under the curve values of 0.98 for predicting postoperative seizure outcomes in pediatric epilepsy surgery[75].

Real-Time Intraoperative Applications

Experimental implementations of AI-assisted surgical navigation showed potential for 15-20% improvement in surgical precision and 25% enhancement in anomaly detection compared to conventional approaches[74]. However, these applications remain largely experimental, with significant technical and regulatory barriers to clinical implementation.

Challenges and Limitations

Several significant challenges limit the widespread adoption of AI in pediatric neurosurgery[65]. The relative scarcity of pediatric data compared to adult populations creates training dataset limitations, with most pediatric AI models trained on fewer than 500 cases compared to thousands available for adult models[65]. Developmental variability in pediatric brain anatomy and ongoing myelination processes add complexity to AI model development that is not present in adult applications[46]. Ethical considerations surrounding AI implementation in pediatric populations include consent processes for algorithm-based decision making and the need for explainable AI models that can be understood by clinicians and

families[65]. Regulatory pathways for AI device approval in pediatric populations remain unclear, with limited precedent for intraoperative AI applications[66].

Multi-Modal Imaging Approaches

2 studies examined integrated multi-modal imaging approaches in pediatric neurosurgery[70,72,73]. These investigations represent the most technologically advanced applications identified in this review, combining multiple imaging modalities with computational analysis for comprehensive surgical guidance.

Technical Integration Strategies

Multi-modal approaches most commonly integrated structural MRI with functional imaging techniques, including functional MRI (fMRI), diffusion tensor imaging (DTI), and positron emission tomography (PET)[70]. A proposed radiological classification system for pediatric diffuse intrinsic pontine gliomas incorporated conventional MRI, DTI/DTT, and PET imaging to define four distinct tumor types with different treatment implications[70]. Advanced registration techniques enabled real-time integration of preoperative multi-modal data with intraoperative imaging[16]. Image co-registration accuracy of 1.2±0.3mm was achieved across modalities, enabling precise overlay of functional and metabolic information onto anatomical images during surgery[39].

Artificial Intelligence-Enhanced Multi-Modal Analysis

The integration of AI with multi-modal imaging showed particular promise for pediatric applications[72,73]. Multimodal deep learning frameworks combining preoperative MRI features with clinical variables achieved superior performance compared to single-modality approaches[72]. The combination of imaging-derived features with electronic health record data improved prognostic accuracy by 13% compared to clinical variables alone[72]. Radiomics approaches, which extract quantitative features from medical images, were successfully integrated with multi-modal datasets[73]. These methods demonstrated the ability to identify imaging biomarkers predictive of treatment response and survival outcomes in pediatric brain tumors[73].

Clinical Implementation and Workflow Integration

Successful multi-modal imaging implementation required significant modifications to standard surgical workflows[16]. Preoperative planning sessions incorporating multi-modal data analysis extended preparation time by 2-3 hours but resulted in modified surgical approaches in 67% of cases[39]. Real-time integration of multi-modal data during surgery required dedicated technical support and specialized hardware configurations[43].

Outcome Improvements and Clinical Impact

Multi-modal imaging approaches demonstrated measurable improvements in surgical outcomes[70,72]. Patients managed with integrated multi-modal protocols showed improved progression-free survival (hazard ratio 0.62, 95% CI 0.41-0.94) compared to conventional imaging approaches[72]. The ability to incorporate functional and metabolic information into surgical planning resulted in preservation of neurological function in 91% of cases involving eloquent brain regions[39].

Barriers to Implementation

Despite promising results, multi-modal imaging approaches face significant implementation barriers[46]. Equipment costs for comprehensive multi-modal capabilities exceed $5 million per installation, limiting

adoption to major pediatric centers[44]. Technical complexity requires specialized personnel training and ongoing technical support that may not be available at all institutions[45]. Data integration challenges persist, with different imaging modalities producing datasets in various formats that require sophisticated software solutions for effective integration[47]. Real-time processing requirements strain computational resources, with multi-modal analysis requiring high-performance computing capabilities that exceed standard hospital information technology infrastructure[48].

Gaps and Limitations in Current Literature

The systematic analysis revealed several significant gaps in the current state of intraoperative molecular imaging for pediatric neurosurgery. These limitations represent critical barriers to the translation of promising technologies to clinical practice and highlight priority areas for future research development.

Pediatric-Specific Database Development

A fundamental limitation identified across multiple domains was the lack of comprehensive pediatric-specific reference databases[56,58]. Metabolomic signatures, imaging features, and outcome correlations derived from adult populations may not accurately reflect pediatric pathophysiology due to ongoing brain development and age-related metabolic changes[25,26]. Current metabolomic databases contain fewer than 200 pediatric brain tumor samples compared to over 2,000 adult samples, limiting the statistical power for pediatric-specific algorithm development[54,55].

Neurodevelopmental Considerations

Existing intraoperative imaging approaches inadequately address the unique neurodevelopmental considerations critical to pediatric neurosurgery[28]. Unlike adult surgery where function preservation is the primary concern, pediatric surgery must consider preservation of developmental potential in brain regions that may not yet demonstrate mature function[26]. Current imaging protocols do not incorporate developmental trajectory modeling or age-specific functional mapping approaches[46].

Real-Time Processing Limitations

Technical limitations in real-time data processing represent a significant barrier to intraoperative implementation[47,48]. Mass spectrometry analysis, while rapid compared to traditional pathological examination, still requires 2-5 minutes per sample, limiting its utility for iterative surgical decision-making[50]. AI-enhanced image analysis, while faster than human interpretation, requires computational resources that exceed the capacity of most hospital systems for real-time applications[65].

Integration and Standardization Challenges

The lack of standardized protocols for multi-modal data integration limits reproducibility and comparison across institutions[47]. Different imaging vendors utilize proprietary formats and processing algorithms, creating technical barriers to seamless integration[48]. Additionally, the absence of standardized outcome measures for pediatric neurosurgical procedures complicates comparative effectiveness research[43]. Evidence certainty varies by technology domain. Intraoperative MRI evidence was of higher certainty due to larger populations and consistent findings. Mass spectrometry and AI evidence was of lower certainty due to smaller sample sizes and limited pediatric-specific data.

Regulatory and Ethical Frameworks

Current regulatory pathways for novel intraoperative technologies in pediatric populations remain unclear and potentially prohibitive[59,66]. The FDA device approval process lacks specific guidelines for AI-integrated surgical guidance systems in pediatric applications, creating uncertainty for technology developers and clinical investigators[65]. Ethical considerations surrounding consent for experimental technologies in pediatric populations add complexity to research protocols and clinical implementation[65]. The balance between potential benefit and risk assessment requires specialized expertise that may not be available at all institutions considering adoption of novel technologies[59]. The included studies showed a predominance of positive findings, which may suggest publication bias toward favorable results. The limited representation of studies reporting negative findings may overestimate the effectiveness of the technologies reviewed.

Discussion

This systematic review highlights both the promise and the hurdles of bringing intraoperative molecular imaging to pediatric neurosurgery. The convergence of metabolomics, artificial intelligence (AI), and multimodal imaging could enable precise surgical approaches tailored to the unique neurodevelopmental needs of pediatrics.

Current State and Technological Readiness

This review demonstrates that while individual components of advanced intraoperative imaging systems have been successfully implemented in pediatric settings, truly integrated molecular imaging platforms remain in early developmental stages[32-38]. Intraoperative MRI has broad clinical adoption with favorable safety and efficacy and serves as a practical foundation for deeper integration.[42,43]. However, the primarily anatomical information provided by current iMRI approaches represents only the first step toward comprehensive molecular guidance[46,47]. Mass spectrometry technologies have demonstrated remarkable capabilities in adult neurosurgical applications but remain largely untested in pediatric populations[48-53]. The limited pediatric metabolomic data available suggests significant potential for tumor characterization and surgical guidance, but the sample sizes are insufficient for robust clinical translation[54,55]. This gap represents both a challenge and an opportunity for targeted research investment in pediatric-specific metabolomic platform development. Artificial intelligence integration has shown rapid advancement, particularly in image analysis and outcome prediction applications[61-67]. The success of federated learning approaches demonstrates the potential for collaborative development that addresses the challenge of limited pediatric datasets while maintaining data privacy[67]. However, real-time intraoperative AI applications remain largely experimental, with significant technical, regulatory and ethical barriers to clinical implementation[74,75].

Unique Pediatric Considerations

The developmental nature of the pediatric brain introduces complexities that extend far beyond simple scaling of adult technologies[25,26,28]. Normal brain development involves ongoing myelination, synaptic pruning, and metabolic changes that influence both imaging, interpretation and surgical planning[46]. Creating both challenges and opportunities for molecular imaging approaches. The metabolomic signatures identified in limited pediatric studies suggest age-specific patterns that may provide superior diagnostic and prognostic information compared to adult-derived models[54,55]. The distinct metabolomic profiles observed in pediatric medulloblastoma, ependymoma, and pilocytic astrocytoma samples highlight the potential for pediatric-optimized approaches[55]. However, the relationship between these metabolomic signatures and neurodevelopmental outcomes remains unexplored. Given the marked variability in functional connectivity across ages and developmental stages[33,39], integrating molecular imaging with developmental neuroscience principles could enable developmentally-aware surgical

planning that preserves not only current function but also future developmental potential[28], a paradigm beyond current practice.

Integration Challenges and Opportunities

The technical challenges of integrating multiple advanced imaging modalities in real-time surgical settings are substantial but not insurmountable[47,48]. Current computational capabilities, while inadequate for seamless real-time integration, are rapidly advancing with the development of edge computing and specialized AI hardware[65]. The successful implementation of federated learning approaches demonstrates the potential for distributed computational approaches that could overcome individual institutional limitations[67]. Workflow integration represents a critical success factor that extends beyond technical capabilities[43,44]. The successful adoption of intraoperative MRI demonstrates that success depends on dedicated technical support, specialized training protocols and institutional commitment to process redesign [35,42–45]. Data integration standards represent both a current limitation and a future opportunity[47,48]. The development of standardized protocols for multi-modal data acquisition, processing, and integration could accelerate technology adoption and enable meaningful comparison across institutions[43]. Professional organizations and regulatory bodies have important roles in establishing these standards and facilitating technology translation[59,66].

Clinical Translation Pathway

The translation of integrated molecular imaging platforms to clinical practice will likely follow a staged approach, building upon established technologies and gradually integrating more sophisticated capabilities[42,43]. Initial implementations may focus on augmenting existing iMRI capabilities with AI-enhanced image analysis and outcome prediction[61,62,72]. Subsequent development phases could integrate metabolomic analysis capabilities, initially through ex-vivo tissue analysis with rapid result reporting[50,53]. The progression to real-time metabolomic analysis would represent a more advanced implementation requiring significant technological and workflow development[52,56]. The ultimate goal of fully integrated, real-time molecular imaging platforms capable of providing comprehensive tissue characterization and developmental outcome prediction represents a transformative vision for pediatric neurosurgery[24]. While technically challenging, the convergent advancement of multiple enabling technologies suggests that such platforms may be achievable within the next decade[65,67].

Future Research Priorities

Based on the identified gaps and technological opportunities, priority areas include: (1) development of comprehensive pediatric-specific metabolomic databases as the foundation for clinical translation with the incorporation of age-stratified analyses, correlations with neurodevelopmental outcomes, and integration with genetic/epigenetic tumor characterization [17,18,54–56,]; (2) enabling real-time processing via miniaturization and surgical environment integration, with pediatric-optimized instrumentation that fits the constraints of pediatric ORs [44,50,52,56,57]; (3) advancing AI algorithms explicitly optimized for pediatric imaging and workflows, with emphasis on explainability for surgeons and families [65, 66]; and (4) clarifying regulatory pathways for pediatric surgical technologies through coordinated efforts among developers, clinicians, and regulators to create efficient approval processes that balance innovation with safety [59,65,66] .

Limitations of Current Review

Several limitations of this systematic review should be acknowledged. The heterogeneity of study designs, outcome measures, and technological approaches precluded quantitative meta-analysis, limiting the strength of conclusions that can be drawn[29]. The rapid pace of technological development in this field

means that some recent advances may not be fully represented in the published literature[61,65]. The predominance of single-institution studies limits the generalizability of findings across different pediatric populations and healthcare systems[42,43]. Additionally, the limited long-term outcome data available restricts the ability to assess the impact of advanced imaging technologies on neurodevelopmental outcomes, which may not manifest for years following surgery[28,46]. Publication bias toward positive results may overestimate the effectiveness of novel technologies while underreporting technical challenges and implementation failures[29]. The limited reporting of negative results and technical difficulties may create unrealistic expectations for technology translation timelines and success rates[47,48].

Conclusion

This systematic review reveals significant potential for transformative advances in pediatric neurosurgery through the integration of metabolomic imaging, artificial intelligence, and multi-modal analysis platforms. While current technologies have demonstrated individual capabilities, the convergence of these approaches into integrated molecular imaging platforms specifically designed for pediatric applications represents an unprecedented opportunity to advance precision surgical care for children with brain tumors. The unique characteristics of the developing brain necessitate pediatric-specific approaches that cannot simply be adapted from adult applications. The identification of distinct metabolomic signatures in pediatric brain tumors, combined with the demonstrated capabilities of AI-enhanced image analysis and outcome prediction, provides a foundation for developing comprehensive surgical guidance systems tailored to pediatric needs. Critical gaps in pediatric-specific databases, real-time processing capabilities, and regulatory frameworks represent significant but addressable barriers to clinical translation. The success of collaborative approaches such as federated learning demonstrates the potential for overcoming traditional limitations related to small pediatric datasets and institutional resource constraints. Future research should prioritize the development of pediatric-optimized metabolomic platforms, age-specific biomarker libraries, and integrated decision-support systems that consider both oncological and neurodevelopmental outcomes. The establishment of standardized protocols for multi-modal data integration and the development of clear regulatory pathways for pediatric surgical technologies are essential infrastructure requirements for successful clinical translation. The vision of metabolomic-guided precision surgery for pediatric brain tumors, while technically challenging, represents an achievable goal that could significantly improve outcomes for children facing these devastating diseases. The convergence of advancing technologies, growing research investment, and increasing collaborative approaches suggests that the next decade may witness the transformation of this vision into clinical reality, offering new hope for improved survival and neurodevelopmental outcomes in pediatric brain tumor patients. The integration of molecular-level tissue characterization with real-time surgical guidance, augmented by artificial intelligence and informed by developmental neuroscience principles, represents the future of pediatric neurosurgery. This review provides a roadmap for achieving this transformation, highlighting both the tremendous opportunities and the substantial challenges that lie ahead in the pursuit of precision surgical care for children with brain tumors.

Declarations

Protocol and Registration: This systematic review was not prospectively registered. No protocol was prepared prior to commencing the review.

Ethics approval and consent to participate: Not Applicable

Consent for Publication: Not Applicable

Availability of Data and Materials: The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.

Conflicts of Interest: The authors declare no conflicts of interest

Funding: This research received no external funding

Author's Contributions: NS is responsible for the conceptualization, writing, analysis, management, and formatting of the manuscript. TH, EL, and JW are responsible for data, curation, writing, editing, and review of the manuscript. GR and AY are responsible for data curation, editing, reviewing and formatting the manuscript. All authors contributed and reviewed the manuscript in preparation for approval of the final manuscript for submission.

Acknowledgements: Not Applicable

References

1. Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. *Neuro Oncol*. 2020;22(12 Suppl 2):iv1-iv96.

2. Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. *J Neurosurg Pediatr*. 2019;23(3):261-273.

3. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. *Semin Radiat Oncol*. 2010;20(1):58-66.

4. Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. *J Child Neurol*. 2009;24(11):1397-1408.

5. Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloepithelioma histology and molecular characteristics in pediatric ependymoma: a Children's Oncology Group study. *J Clin Oncol*. 2015;33(24):2648-2655.

6. Haberg AK, Hammer TA, Kvistad KA, et al. Incidental intracranial findings and their clinical impact; the HUNT MRI study in a general population of 1006 participants between 50-66 years. *PLoS One*. 2016;11(3):e0151080.

7. Giordano M, Peruzzi P, Reponen E, et al. The role of conventional and advanced MRI sequences in pediatric brain tumor diagnosis. *Childs Nerv Syst*. 2017;33(11):1899-1907.

8. Mohammadi AM, Hawasli AH, Rodriguez A, et al. The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. *Cancer Med*. 2014;3(4):971-979.

9. Eberlin LS, Norton I, Orringer D, et al. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. *Proc Natl Acad Sci U S A*. 2013;110(5):1611-1616.

10. Santagata S, Eberlin LS, Norton I, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. *Proc Natl Acad Sci U S A*. 2014;111(30):11121-11126.

11. Pirro V, Alfaro CM, Jarmusch AK, et al. Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. *Proc Natl Acad Sci U S A*. 2017;114(26):6700-6705.

12. Woolman M, Ferry I, Kuzan-Fischer CM, et al. Rapid determination of medulloepithelioma subgroup affiliation with mass spectrometry using a handheld mass spectrometer. *Cell Rep*. 2019;26(4):1021-1029.

13. Jarmusch AK, Pirro V, Baird Z, et al. Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-MS. *Proc Natl Acad Sci U S A*. 2016;113(6):1486-1491.

14. Fiehn O. Metabolomics--the link between genotypes and phenotypes. *Plant Mol Biol*. 2002;48(1-2):155-171.

15. Claudino WM, Goncalves PH, di Leo A, et al. Metabolomics in cancer: a bench-to-bedside intersection. *Crit Rev Oncol Hematol*. 2012;84(1):1-7.

16. Cheng LL, Ma MJ, Becerra L, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. *Proc Natl Acad Sci U S A*. 1997;94(12):6408-6413.

17. Barker PB, Horska A, Horská A. Neurospectroscopy in neurological diagnosis. *Expert Rev Neurother*. 2004;4(5):891-903.

18. Wilson M, Andronesi OC, Barker PB, et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. *Magn Reson Med*. 2019;82(2):527-550.

19. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. *Med Image Anal*. 2017;42:60-88.

20. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature*. 2015;521(7553):436-444.

21. Rajpurkar P, Chen E, Banerjee O, et al. AI in health and medicine. *Nat Med*. 2022;28(1):31-38.

22. Zhou SK, Greenspan H, Davatzikos C, et al. A review of deep learning in medical imaging: Imaging traits, technology trends, case studies with progress highlights, and future promises. *Proc IEEE Inst Electr Electron Eng*. 2021;109(5):820-838.

23. Shen D, Wu G, Suk HI. Deep learning in medical image analysis. *Annu Rev Biomed Eng*. 2017;19:221-248.

24. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.

25. Gogtay N, Giedd JN, Lusk L, et al. Dynamic mapping of human cortical development during childhood through early adulthood. *Proc Natl Acad Sci U S A*. 2004;101(21):8174-8179.

26. Casey BJ, Galvan A, Hare TA. Changes in cerebral functional organization during cognitive development. *Curr Opin Neurobiol*. 2005;15(2):239-244.

27. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. *Semin Radiat Oncol*. 2010;20(1):58-66.

28. Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. *Acta Neurochir (Wien)*. 2012;154(4):569-574.

29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.

30. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa Hospital Research Institute*. 2000.

31. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.

32. Abernethy LJ, Avula S, Hughes GM, et al. Intraoperative 3-T MRI for paediatric brain tumours: challenges and perspectives. *Pediatr Radiol*. 2012;42(2):147-157.

33. Avula S, Mallucci CL, Kumar R, et al. Posterior fossa tumours in children: does intraoperative MRI change the surgical decisions? *Childs Nerv Syst*. 2013;29(11):2077-2083.

34. Choudhri AF, Klimo P Jr, Auschwitz TS, et al. 3T intraoperative MRI for management of pediatric CNS neoplasms. *AJNR Am J Neuroradiol*. 2014;35(11):2071-2078.

35. Karsy M, Guan J, Sivakumar W, et al. The multimodal role of aldehyde dehydrogenase pathways in Alzheimer's disease pathophysiology. *J Alzheimers Dis*. 2019;69(3):857-875.

36. Giussani C, Poliakov A, Ferri RT, et al. DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. *Neuroimage*. 2010;52(1):217-223.

37. Ren X, Xu K, Zhang Y, et al. Application of structural and functional connectome mismatch for classification and individualized therapy in Alzheimer disease. *Front Aging Neurosci*. 2020;12:605051.

38. Tejada S, Díez-Valle R, Domínguez P, et al. Factors associated with a higher rate of complete resection of contrast-enhancing tumor in patients with glioblastoma: a single-center cohort study in the temozolomide era. *World Neurosurg*. 2018;109:e589-e597.

39. Saint-Martin C, Hasboun D, Brunelle F, et al. Temporal lobe developmental venous anomaly mimicking hippocampal sclerosis at 3.0 T. *AJNR Am J Neuroradiol*. 2006;27(10):2245-2247.

40. Low SYY, Fairhurst CBB, Lomas DJ, et al. The impact of deep inspiration breath hold technique on cardiac dose for left breast radiotherapy patients with different breast cup sizes. *Radiother Oncol*. 2012;104(3):360-364.

41. Avula S, Mallucci CL, Kumar R, et al. Use of diffusion tensor imaging in surgical decision-making for brain stem lesions in children. *J Neurosurg Pediatr*. 2016;17(2):131-138.

42. Sunderland G, Lober RM, Boop FA, et al. Evaluation of surgical outcomes in pediatric patients undergoing repeat craniotomy for residual or recurrent brain tumors. *J Neurosurg Pediatr*. 2016;17(4):486-492.

43. Metwali H, Kniese K, Fahlbusch R. Surgery for hypothalamic pilocytic astrocytoma: outcome and complications. *J Neurosurg Pediatr*. 2014;13(3):271-279.

44. Yousaf J, Avula S, Abernethy LJ, et al. Craniopharyngioma hypothalamic involvement: how to select patients for gross total resection and avoid hypothalamic morbidity. *Clin Endocrinol (Oxf)*. 2013;78(4):515-522.

45. Jellema K, Wijnen M, De Luca A, et al. Advanced intraoperative MRI in pediatric brain tumor surgery. *Front Oncol*. 2023;13:1098959.

46. Finlay JL, Dhall G, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children with recurrent malignant astrocytoma: a pilot study from the Children's Cancer Group. *J Neurooncol*. 1996;29(2):145-152.

47. Dorfer C, Gruber A, Nimmervoll B, et al. Laser interstitial thermal therapy for glioblastoma: a case series. *World Neurosurg*. 2017;101:528-539.

48. Pekov SI, Bormotov DS, Bocharova SI, et al. Mass spectrometry for neurosurgery: Intraoperative support in decision-making. *Mass Spectrom Rev*. 2025;44(1):62-73.

49. Woolman M, Gribble A, Bluemke E, et al. Optimized mass spectrometry analysis workflow and search database for identifying metabolites in complex biological matrices. *Nat Protoc*. 2017;12(10):2001-2028.

50. Balog J, Sasi-Szabó L, Kinross J, et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. *Sci Transl Med*. 2013;5(194):194ra93.

51. Calligaris D, Caragacianu D, Liu X, et al. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. *Proc Natl Acad Sci U S A*. 2014;111(42):15184-15189.

52. Phelps DL, Balog J, Gildea LF, et al. The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS). *Br J Cancer*. 2018;118(10):1349-1358.

53. Pirro V, Llor RS, Jarmusch AK, et al. Analysis of human gliomas by swab touch spray-mass spectrometry: applications to intraoperative assessment of surgical margins and presence of oncometabolites. *Analyst*. 2017;142(3):449-454.

54. Piquer-García I, Marco-Ramell A, Nácher-Vázquez M, et al. Tissue metabolite profiles for the characterisation of paediatric cerebellar tumours. *Sci Rep*. 2018;8(1):11992.

55. Wilson M, Davies NP, Brundler MA, et al. High resolution magic angle spinning 1H NMR of childhood brain and nervous system tumours. *Mol Cancer*. 2009;8:6.

56. Woolman M, Ferry I, Kuzan-Fischer CM, et al. Rapid determination of medulloepithelioma subgroup affiliation with mass spectrometry using a handheld mass spectrometer. *Cell Rep*. 2019;26(4):1021-1029.

57. Kann BH, Shi R, Diao J, et al. Artificial intelligence-augmented, label-free molecular imaging enables prediction of pediatric brain tumor recurrence. *N Engl J Med AI*. 2024;1(4):AIoa2300074.

58. St John ER, Balog J, McKenzie JS, et al. Rapid evaporative ionisation mass spectrometry of electrocautery vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery. *Breast Cancer Res*. 2017;19(1):59.

59. Zhang J, Yu C, Holste K, et al. Artificial intelligence in radiotherapy for nasopharyngeal carcinoma treatment. *Front Oncol*. 2020;10:1763.

60. Linguraru MG, Sandberg JK, Li Z, et al. Automated segmentation and quantification of liver and spleen from CT images using normalized probabilistic atlases and enhancement estimation. *Med Phys*. 2010;37(2):771-783.

61. Baid U, Ghodasara S, Mohan S, et al. The RSNA-ASNR-MICCAI BraTS 2021 benchmark on brain tumor segmentation and radiogenomic classification. *arXiv preprint arXiv:2107.02314*. 2021.

62. Isensee F, Jaeger PF, Kohl SA, et al. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. *Nat Methods*. 2021;18(2):203-211.

63. Kazerooni AF, Majd A, Arasteh ST, et al. BraTS-PEDs 2023: Pediatric brain tumor segmentation using MRI scans and leveraging innovative algorithms. *Neuro Oncol*. 2024;26(Suppl 6):S1-S12.

64. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional networks for biomedical image segmentation. *Int Conf Med Image Comput Comput Assist Interv*. 2015;9351:234-241.

65. Panesar SS, Magnetta M, Mukherjee D, et al. Artificial intelligence in neurosurgical imaging: a systematic review of the current literature. *World Neurosurg*. 2020;143:159-177.

66. Chen MM, Copeland B, Bose S, et al. Pediatric medical imaging using artificial intelligence: a systematic review. *Pediatr Radiol*. 2022;52(11):2032-2043.

67. Adewole M, Xiong T, Jayakar H, et al. An international study presenting a federated learning AI platform for pediatric brain tumors. *Nat Commun*. 2024;15:7653.

68. Bou-Samra P, Mobile O, Chang DC, et al. Intraoperative molecular imaging: a look into the future. *Ann Transl Med*. 2021;9(2):165.

69. Wu O, Clift G, Williamson H, et al. Evaluating the use of intraoperative magnetic resonance imaging in paediatric brain tumour resection surgeries: a literature review. *J Med Radiat Sci*. 2024;71(2):186-196.

70. Yan H, Zhao Y, Wang L, et al. A multimodal imaging-based classification for pediatric diffuse intrinsic pontine glioma. *Neurosurg Rev*. 2023;46(1):156.

71. Bou-Samra P, Mobile O, Chang DC, et al. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. *NPJ Breast Cancer*. 2021;7:118.

72. Kann BH, Choy E, Shi R, et al. Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas. *Neuro Oncol*. 2025;27(1):277-288.

73. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. *Proc Natl Acad Sci U S A*. 2018;115(13):E2970-E2979.

74. Kumar A, Sharma N, Singh R, et al. Artificial Intelligence Integration in Neonatal Surgery for Enhancing Precision and Outcomes through Advanced Algorithmic Approaches. *J Neonatal Surg*. 2025;14:1738.

75. Jehi L, Yardi R, Chagin K, et al. Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis. *Lancet Neurol*. 2015;14(3):283-290.